Ravulizumab for the treatment of myasthenia gravis
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2023.2185131
Abstract: ABSTRACT Introduction Myasthenia gravis (MG) is a neurological B-cell mediated autoimmune disorder affecting the neuromuscular junction. MG therapeutics have always relied on nonselective immunosuppression with oral steroids and non-steroidal immunosuppressants, mainly with good clinical response.… read more here.
Keywords: myasthenia gravis; ravulizumab treatment; ravulizumab; treatment myasthenia ... See more keywords